Molecular Biology Resources, Inc.

www.molbiores.com

Founded in 1985 in Milwaukee, Wisconsin, Molecular Biology Resources, Inc. (MBR) has earned the reputation as a world leader in biochemical manufacturing. An early pioneer in the restriction endonuclease and polymerase market, MBR continues to help move the industry forward with our ever expanding product line of unique reagents and testing services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

ALLIGATOR BIOSCIENCE ANNOUNCES IND APPROVAL FOR CD40 TARGETING ANTIBODY MITAZALIMAB

Alligator Bioscience | December 07, 2020

news image

Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "W...

Read More

APTORUM GROUP JOINS THE BEAM ALLIANCE TO COMBAT ANTIMICROBIAL RESISTANCE

Business Wire | September 08, 2020

news image

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the “BEAM Alliance”) as full member. The BEAM Alliance is a network of approximately 70 small and medium-sized European companies...

Read More

CELL AND GENE THERAPY

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

news image

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More

INDUSTRIAL IMPACT

AGILENT AND A*STAR’S SIFBI SIGN RESEARCH COLLABORATION AGREEMENT TO ADVANCE SINGAPORE AGRI-FOOD INDUSTRY

Agilent Technologies Inc. | January 27, 2022

news image

Agilent Technologies Inc. recently signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation outlining their collaboration on developing food research knowledge advancement over the next two years. SIFBI is a research institute under the Agency for Science, Technology, and Research in Singapore. This collaboration aims to bring state-of-the-art science and technology to drive innovation in food, nutrition, ingredients, industrial b...

Read More
news image

MEDICAL

ALLIGATOR BIOSCIENCE ANNOUNCES IND APPROVAL FOR CD40 TARGETING ANTIBODY MITAZALIMAB

Alligator Bioscience | December 07, 2020

Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "W...

Read More
news image

APTORUM GROUP JOINS THE BEAM ALLIANCE TO COMBAT ANTIMICROBIAL RESISTANCE

Business Wire | September 08, 2020

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the “BEAM Alliance”) as full member. The BEAM Alliance is a network of approximately 70 small and medium-sized European companies...

Read More
news image

CELL AND GENE THERAPY

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More
news image

INDUSTRIAL IMPACT

AGILENT AND A*STAR’S SIFBI SIGN RESEARCH COLLABORATION AGREEMENT TO ADVANCE SINGAPORE AGRI-FOOD INDUSTRY

Agilent Technologies Inc. | January 27, 2022

Agilent Technologies Inc. recently signed a Research Collaboration Agreement with the Singapore Institute of Food and Biotechnology Innovation outlining their collaboration on developing food research knowledge advancement over the next two years. SIFBI is a research institute under the Agency for Science, Technology, and Research in Singapore. This collaboration aims to bring state-of-the-art science and technology to drive innovation in food, nutrition, ingredients, industrial b...

Read More